Effects of Aliskiren-Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients

Journal of Clinical Hypertension

Volumn 14, Issue 8, 2012, Pages 522-529

  Kanaoka, Tomohiko ^a   Tamura, Kouichi ^a   Ohsawa, Masato ^a   Wakui, Hiromichi ^a   Maeda, Akinobu ^a   Dejima, Toru ^a   Azushima, Kengo ^a   Haku, Sona ^a   Mitsuhashi, Hiroshi ^a   Yanagi, Mai ^a   Oshikawa, Jin ^a   Uneda, Kazushi ^a   Aoki, Kazutaka ^a   Fujikawa, Tetsuya ^a   Toya, Yoshiyuki ^a   Uchino, Kazuaki ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; BRAIN NATRIURETIC PEPTIDE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; ENDOCRINE FUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HEART HEMODYNAMICS; HUMAN; JAPANESE; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE;

EID: 85027933664     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00640.x     Document Type: Article

References (56)

1. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
2. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008;7:399-410.
3. Hollenberg NK. Direct renin inhibition and the kidney. Nat Rev Nephrol. 2010;6:49-55.
4. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011;342:d3621.
5. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219-1230.
6. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
7. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27:461-467.
8. Wang KL, Cheng HM, Sung SH, et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension. 2010;55:799-805.
9. Gomez-Marcos MA, Recio-Rodriguez JI, Rodriguez-Sanchez E, et al. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol. BMC Public Health. 2010;10:143.
10. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:1865-1871.
11. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich). 2005;7:102-109.
12. Tamura K, Tsurumi Y, Sakai M, et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens. 2007;29:31-42.
13. Tamura K, Yamauchi J, Tsurumi-Ikeya Y, et al. Ambulatory blood pressure and heart rate in hypertensives with renal failure: comparison between diabetic nephropathy and non-diabetic glomerulopathy. Clin Exp Hypertens. 2008;30:33-43.
14. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis. 2009;207:186-190.
15. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res. 2009;32:950-955.
16. Ozawa M, Tamura K, Okano Y, et al. Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens. 2009;31:669-679.
17. Ozawa M, Tamura K, Okano Y, et al. Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives. Clin Exp Hypertens. 2009;31:259-270.
18. Kanaoka T, Tamura K, Moriya T, et al. Effects of multiple factorial intervention on ambulatory BP Profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study. Clin Exp Hypertens. 2011;33:255-263.
19. Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension. 2000;36:901-906.
20. Sander D, Kukla C, Klingelhofer J, et al. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation. 2000;102:1536-1541.
21. Eto M, Toba K, Akishita M, et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res. 2005;28:1-7.
22. Takazawa K, Kobayashi H, Shindo N, et al. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res. 2007;30:219-228.
23. Kips JG, Schutte AE, Vermeersch SJ, et al. Comparison of central pressure estimates obtained from SphygmoCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens. 2011;29:1115-1120.
24. Rezai MR, Goudot G, Winters C, et al. Calibration mode influences central blood pressure differences between SphygmoCor and two newer devices, the Arteriograph and Omron HEM-9000. Hypertens Res. 2011;34:1046-1051.
25. Tomiyama H, Odaira M, Matsumoto C, et al. Effects of moderate-to-severe impairment of the estimated glomerular filtration rate and of proteinuria on the central hemodynamics and arterial stiffness in middle-aged healthy Japanese men. Int J Nephrol. 2011;2011:427471.
26. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25:359-364.
27. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
28. Andersen K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10:157-167.
29. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens. 2009;22:112-121.
30. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens. 2009;22:954-957.
31. Kawasaki T, Ueno M, Uezono K, et al. Differences and similarities among circadian characteristics of plasma renin activity in healthy young women in Japan and the United States. Am J Med. 1980;68:91-96.
32. Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005;115:1092-1099.
33. Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA. 2006;103:17985-17990.
34. Funke-Kaiser H, Zollmann FS, Schefe JH, et al. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res. 2010;33:98-104.
35. Nguyen G. Renin and prorenin receptor in hypertension: what's new? Curr Hypertens Rep. 2011;13:79-85.
36. Batenburg WW, Krop M, Garrelds IM, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007;25:2441-2453.
37. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130-136.
38. Hollenberg NK, Fisher ND, Nussberger J, et al. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J Hypertens. 2011;29:2454-2461.
39. Michel FS, Norton GR, Majane OH, et al. Contribution of circulating angiotensinogen concentrations to variations in aldosterone and blood pressure in a group of African ancestry depends on salt intake. Hypertension. 2012;59:62-69.
40. Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118-123.
41. Ino J, Kojima C, Osaka M, et al. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol. 2009;29:1858-1863.
42. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52:563-572.
43. Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118:984-993.
44. Nussberger J, Aubert JF, Bouzourene K, et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51:1306-1311.
45. Kuhnast S, van der Hoorn JW, van den Hoek AM, et al. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J Hypertens. 2012;30:107-116.
46. Cherney DZ, Lai V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care. 2010;33:361-365.
47. Ferdinand KC, Pool J, Weitzman R, et al. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. J Clin Hypertens (Greenwich). 2011;13:366-375.
48. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445-448.
49. Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension. 1998;32:570-574.
50. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
51. Mitchell GF, Wang N, Palmisano JN, et al. Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. Circulation. 2010;122:1379-1386.
52. Safar ME, O'Rourke MF. The brachial-ankle pulse wave velocity. J Hypertens. 2009;27:1960-1961.
53. Tomiyama H, Koji Y, Yambe M, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J. 2005;69:815-822.
54. Tanaka H, Munakata M, Kawano Y, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens. 2009;27:2022-2027.
55. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
56. Parving HH, Brenner BM, McMurray JJ, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. 2012 Feb 14. [Epub ahead of print].